Sanofi’s cholesterol-fighting biologic drug won’t be pulled from pharmacy shelves, at least not for a few more months.
The U.S. Court of Appeals for the Federal Circuit on Wednesday stayed a Delaware judge’s order enjoining sales of Praluent until the court can process Sanofi and partner Regeneron Pharmaceuticals Inc.’s appeal. Sanofi and a group of amici curiae physicians had argued that enforcing the order would put lives at risk, disrupt medical research, throw Sanofi employees out of work and force the company to renegotiate contracts with insurers and pharmacy benefit managers.
